fda warning bpc 157 compounding safety risks advisory committee votes to add popular peptide BPC-157 to drug list FDA mulls compounding for peptides

An ongoing crisis: Semaglutide shortage raises dual concerns for obesity and diabetes treatment

Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease

This work highlights why accurate analytical methods and biological understanding are essential before drawing conclusions about microplastics in human tissues

For a person who cannot absorb B12, the injection is a critical, life-sustaining treatment, not a voluntary supplement

Signs of Progress Track these indicators to assess treatment effectiveness: Reduced pain intensity on a 1-10 scale Decreased pain medication use Improved grip strength (compare dominant to non-dominant hand) Expanded pain-free range of motion Reduced swelling or tenderness on palpation Better sleep quality due to less nighttime discomfort Increased time before pain onset during repetitive activities Reduced reliance on bracing or splinting When Results Disappoint Not everyone responds equally to BPC-157

Patients will be required to disclose any medications that they routinely use